



## Foetal oestrogens and autism

Simon Baron-Cohen<sup>1</sup> · Alexandros Tsompanidis<sup>1</sup> · Bonnie Auyeung<sup>1,2</sup> · Bent Nørgaard-Pedersen<sup>3</sup> · David M. Hougaard <sup>3</sup> · Morsi Abdallah <sup>4</sup> · Arieh Cohen<sup>3</sup> · Alexa Pohl<sup>1</sup>

Received: 5 February 2019 / Revised: 25 April 2019 / Accepted: 21 May 2019 / Published online: 29 July 2019  
© The Author(s) 2019. This article is published with open access

### Abstract

Elevated latent prenatal steroidogenic activity has been found in the amniotic fluid of autistic boys, based on measuring prenatal androgens and other steroid hormones. To date, it is unclear if other prenatal steroids also contribute to autism likelihood. Prenatal oestrogens need to be investigated, as they play a key role in synaptogenesis and corticogenesis during prenatal development, in both males and females. Here we test whether levels of prenatal oestriol, oestradiol, oestrone and oestrone sulphate in amniotic fluid are associated with autism, in the same Danish Historic Birth Cohort, in which prenatal androgens were measured, using univariate logistic regression ( $n = 98$  cases,  $n = 177$  controls). We also make a like-to-like comparison between the prenatal oestrogens and androgens. Oestradiol, oestrone, oestriol and progesterone each related to autism in univariate analyses after correction with false discovery rate. A comparison of standardised odds ratios showed that oestradiol, oestrone and progesterone had the largest effects on autism likelihood. These results for the first time show that prenatal oestrogens contribute to autism likelihood, extending the finding of elevated prenatal steroidogenic activity in autism. This likely affects sexual differentiation, brain development and function.

### Introduction

The male-biased prevalence of autism [1, 2], together with the finding that autistic girls have a higher mutational load than autistic boys [3–5], suggests that males have a higher

likelihood of developing autism. The sex ratio in autism diagnoses persists even after taking into account under- and/or mis-diagnosis, as well as camouflaging in females, with males being three times more likely to have the condition [6]. This implicates mechanisms of sexual differentiation in the development of autism. Five recent findings support this inference.

First, autistic women have atypical brain structure in sexually dimorphic regions, when assessed via magnetic resonance imaging and compared to neurotypical controls [7]. Second, functional connectivity in the brain of males with autism shows both hypermasculine and hyperfeminine patterns, when assessed in relation to neurotypical sex differences [8]. Third, autistic people show a masculinised shift in scores on two key sexually dimorphic psychological traits, empathy and systemising, a finding that has been replicated in a big data study of 36,000 autistic people [9, 10]. Fourth, autistic women have elevated androstenedione levels, the precursor to testosterone [11]. Finally, fifth, autistic children have hypermasculine facial features, as rated using three-dimensional photogrammetry [12].

Although autism is strongly heritable and sex-associated genetic mechanisms could contribute to this implication of sexual differentiation in autism [2, 5], prenatal hormone exposure and a brief surge in foetal testosterone are critical for sexual differentiation and masculinisation in humans

---

These authors contributed equally: Simon Baron-Cohen, Alexandros Tsompanidis

**Supplementary information** The online version of this article (<https://doi.org/10.1038/s41380-019-0454-9>) contains supplementary material, which is available to authorized users.

- 
- ✉ Simon Baron-Cohen  
sb205@cam.ac.uk
  - ✉ Alexandros Tsompanidis  
at768@medschl.cam.ac.uk

<sup>1</sup> Autism Research Centre, Department of Psychiatry, University of Cambridge, Cambridge, UK

<sup>2</sup> Department of Psychology, School of Philosophy, Psychology and Language Sciences, University of Edinburgh, Edinburgh, UK

<sup>3</sup> Department for Congenital Disorders, Danish Center for Neonatal Screening, Statens Serum Institute, Copenhagen, Denmark

<sup>4</sup> Department of Child and Adolescent Mental Health Services, Region of Southern Denmark, Hospital of Southern Jutland, Aabenraa, Denmark

[13, 14]. In line with this, we previously found elevated steroidogenic activity during this prenatal masculinisation window (PMW) in the amniotic fluid of autistic boys [15]. Subsequently, three very large epidemiological studies revealed a link between autism and maternal polycystic ovarian syndrome (PCOS), a condition associated with androgenic excess [16–18]. Consistently with this, the 2D:4D digit ratio, a marker of prenatal androgen exposure, is also masculinised in autistic children and their parents [19]. Finally, autistic women and their mothers have elevated rates of steroid-related cancers, such as breast cancer and ovarian cancer [20].

However, a number of studies that focused on testosterone have not replicated the correlation of hormonal levels with autistic traits. First, umbilical cord testosterone measured soon after birth was not associated with the development of autistic traits [21]. Second, salivary testosterone during a brief period of postnatal steroid surge ('mini-puberty') also did not correlate with autistic traits in toddlers [22]. In both cases, testosterone was measured postnatally—in the neonatal period—rather than during the PMW, during which foetal testosterone is first produced and masculinisation of the brain and body commences. This would suggest that timing is critical for the effects of testosterone on the brain, with the late first-early second trimester PMW being key, rather than the neonatal period. Finally, univariate assessment of amniotic testosterone in a separate cohort of neurotypical children also failed to reveal an association to autistic traits in childhood [23]. This latter finding may reflect that the wider endocrine environment outside testosterone is also significant for autism likelihood.

While prenatal androgens are responsible for masculinisation in humans, prenatal oestrogens also contribute to foetal and neonatal brain development [24], and yet these have not been thoroughly investigated for their potential role in autism likelihood. Oestrogens and their receptors are widespread in the developing brain in both males and females and regulate many neurodevelopmental processes, including synaptogenesis, apoptosis and neuronal differentiation [25–27]. Oestradiol in particular supports synapse formation in the cortex by enhancing excitatory GABA activity [28]. In autism, synapse formation [29], neuronal differentiation [30] as well as the GABAergic system [31] are all atypical. These provide clues that prenatal oestrogens may be involved in autism. However, we still lack direct evidence of this.

With regard to clinical studies in humans, low oestriol in maternal serum during the second trimester of pregnancy significantly increases the likelihood of autism in the foetus, as demonstrated in a large study of  $n = 2586$  autistic pregnancies [32]. This study may have been confounded by a variety of pregnancy complications, such as pre-eclampsia [33] and being small for gestational age [34], since these are

also more frequent in autism [35–37]. Thus, further study of prenatal oestrogenic activity, particularly in foetal circulation, is warranted. In addition, there is a need to compare different prenatal oestrogens to each other, in relation to autism likelihood.

In the present study, we measured prenatal levels of oestriol, oestradiol, oestrone and oestrone sulphate in amniotic fluid of boys with and without autism ( $n = 98$  and  $n = 177$  respectively) from the Danish Historic Birth Cohort (HBC), in the same samples in which we had found an elevated steroidogenic factor, following principal component analysis of prenatal androgens and other steroid hormones [15]. We have expanded on these findings by assaying oestrogens and by assessments of each steroid hormone to autism likelihood via univariate logistic regression. We also investigated potential differences in the aromatising capacity in autism by comparing the ratio between androgens and oestrogens. Finally, we calculated standardised effect sizes for all hormones assayed to date in this cohort, in order to understand which amniotic fluid hormones make the largest contribution to autism likelihood.

## Methods

### Participants and laboratory methods

The study was approved by the Danish Data Protection Agency and The Danish Ethical Committee of Midtjylland Region. The Danish Historic Birth Cohort was established at Statens Serum Institute, Copenhagen with a grant from The Danish Medical Research Foundation and The Danish Ministry of the Interior and Health (Project no 271-05-0523/09-060179). A full description of the cohort selection procedure is available elsewhere [15]. Briefly, cases and controls were drawn from singleton births between the years 1993 and 1999 inclusive, whose amniotic fluid samples were stored in the HBC. These corresponded to amniocentesis procedures performed between 14 and 16 weeks of gestational age. Cases were identified from the Danish Psychiatric Central Register using ICD-10 autism spectrum codes F84.0 (childhood autism), F84.5 (Asperger's syndrome), F84.1 (atypical autism), F84.8 (other pervasive developmental disorder) and F84.9 (unspecified pervasive developmental disorder). Any additional amniotic fluid was assayed for oestradiol, oestriol, oestrone, and oestrone sulphate, using liquid chromatography-tandem mass spectroscopy (Supplementary Table 1). As some individuals did not have sufficient remaining sample for analysis, the sample size was slightly decreased. The same data quality screening criteria that were used in the initial analysis were applied: i.e. removal of outliers >99%, removal of records

where duplicate assay values were  $>3$  SD (standard deviation) apart [15]. After this step, the final sample with high-quality data for all steroids assayed to date consisted of 98 males with autism and 177 control males. This sample was used for all analyses in this paper, unless otherwise specified (Supplementary Fig. 1).

## Statistical analyses

We calculated a correlation matrix for all assayed steroid hormones using Pearson's correlation coefficient. We also examined the univariate distribution of each of the oestrogens. All hormones showed a substantial rightward skew. We transformed the oestrogens using the Box–Cox procedure to reduce their skew, as the distribution of the predictor variable affects the statistical power of logistic regression [38]. We used univariate logistic regression models to determine whether each hormone separately increased autism likelihood in this cohort. As the oestrogens considered here vary in their equilibrium association constants to the oestrogen receptors, and therefore their potency [39, 40], we hypothesised that if a relationship between amniotic oestrogens and autism was found, oestradiol would have the largest effect size as the most potent oestrogen. Therefore, we also considered each hormone separately, with the goal of establishing accurate effect sizes to enable a comparison between them, and we corrected for multiple comparisons using the Benjamini–Hochberg false discovery rate (FDR). To estimate and compare the aromatising capacity between cases and controls, we calculated the aromatisation ratios, according to previously published recommendations [41], by log-transforming the raw concentration values and subsequently subtracting them according to the following formula:

$$\text{Ratio 1} = \log(\text{testosterone concentration in nmol/l}) - \log(\text{oestradiol concentration in nmol/l})$$

$$\text{Ratio 2} = \log(\text{androstenedione concentration in nmol/l}) - \log(\text{oestrone concentration in nmol/l})$$

We subsequently used nonparametric tests to compare these ratios to each other (Spearman's rank correlation coefficient) and between cases and controls (Wilcoxon rank-sum test).

## Results

There were no significant differences between groups in maternal age at birth, paternal age at birth, birth weight, gestational week at amniocentesis or storage time between groups (Table 1). Raw data for each of the oestrogens are presented in Fig. 1. Values for the median and interquartile range as well as raw data categorised by autism diagnosis are available in the Supplemental Information (Supplementary Table 2). Oestradiol levels were the most predictive of an

**Table 1** Description of Danish Historic Birth Cohort sample

|                                   | Control<br><i>n</i> = 177<br>Mean ± SD | Autism<br><i>n</i> = 98<br>Mean ± SD | <i>P</i> value |
|-----------------------------------|--|--------------------------------------|----------------|
| Maternal age at birth             | 33.33 ± 5.15                           | 33.53 ± 5.65                         | 0.775          |
| Paternal age at birth             | 35.30 ± 6.72                           | 35.85 ± 7.44                         | 0.552          |
| Birth weight (g)                  | 3516.81 ± 659.45                       | 3524.55 ± 679.15                     | 0.928          |
| Gestational week at amniocentesis | 14.89 ± 1.91                           | 14.90 ± 1.48                         | 0.953          |
| Storage time (years)              | 14.90 ± 1.58                           | 14.96 ± 1.69                         | 0.770          |
| APGAR score > 6                   | 97%                                    | 96%                                  |                |

autism diagnosis, as revealed by univariate logistic regression ( $\beta = 0.029$ , FDR-adjusted  $q = 0.031$ ). The same was found for the levels of oestriol and oestrone, with both hormones being significantly associated to an autism diagnosis using logistic regression (Oestriol:  $\beta = 0.025$ ,  $q = 0.034$ ; oestrone:  $\beta = 0.029$ , FDR-adjusted  $q = 0.031$ ) (Table 2). Oestrone sulphate was also a nominally significant predictor of autism likelihood in the logistic regression model but did not maintain statistical significance following false discovery rate correction ( $\beta = 0.033$ ,  $p = 0.036$ ,  $q = 0.065$ ) (Table 2).


## Androgens and other steroids

We revisited the previously assayed concentrations of androgens and cortisol [15] in the same subset of samples in which we assayed oestrogens, to understand whether the relationship between oestrogens and autism likelihood was similar to the relationship between androgens and autism likelihood (Table 2). Beeswarm plots of distribution in Supplementary Fig. 2). Of the previously analysed steroid hormones, only progesterone was a significant predictor of autism diagnosis, following univariate logistic regression and correction via FDR in this subset of the cohort ( $\beta = 0.053$ , FDR-adjusted  $q = 0.031$ ) (Table 2).

## Comparison

Pairwise correlation analysis (Pearson's) revealed varying degrees of similarity between the steroid hormones. The concentrations of oestrogens were significantly correlated with one another at  $q < 0.05$ , adjusted for multiple comparisons via FDR (Fig. 2, Supplementary Table 3). Oestrone and oestriol showed higher correlations to the other steroids than did oestrone sulphate and oestradiol. In comparison, the previously analysed steroid hormones formed a distinct group, with weaker correlations to oestrogens and stronger correlations to each other. Androstenedione and progesterone (Pearson's  $\beta = 0.59317$ , FDR-adjusted  $q < 0.001$ ), oestrone and oestrone sulphate (Pearson's  $\beta = 0.589$ , FDR-adjusted  $q < 0.001$ ) were the pairs that were more closely related. Oestradiol did not correlate with either testosterone or oestriol.

**Fig. 1** Beeswarm plots illustrating the distribution of oestriol, oestradiol, oestrone and oestrone sulphate concentrations. Error bars represent the interquartile range, and the black dot represents the median; (*n* CTR = 177, *n* ASC = 98)



**Table 2** Results of univariate logistic regression for amniotic steroid hormones

|                    | Regression coefficient | Standard error | <i>z</i> -value | <i>p</i> value | FDR-adjusted <i>q</i> value |
|--------------------|------------------------|----------------|-----------------|----------------|-----------------------------|
| Oestriol           | 0.025*                 | 0.010          | 2.426           | 0.015          | 0.034                       |
| Oestradiol         | 0.029*                 | 0.010          | 2.757           | 0.006          | 0.031                       |
| Oestrone           | 0.029*                 | 0.011          | 2.603           | 0.009          | 0.031                       |
| Oestrone sulphate  | 0.033                  | 0.016          | 2.095           | 0.036          | 0.065                       |
| Testosterone       | 0.352                  | 0.304          | 1.157           | 0.247          | 0.247                       |
| Androstenedione    | 0.444                  | 0.270          | 1.648           | 0.100          | 0.128                       |
| 17-OH Progesterone | 0.547                  | 0.271          | 2.022           | 0.043          | 0.065                       |
| Progesterone       | 0.053*                 | 0.021          | 2.562           | 0.010          | 0.031                       |
| Cortisol           | 0.147                  | 0.111          | 1.332           | 0.183          | 0.206                       |



\*Statistical significance (*q* < 0.05), following correction via FDR

We also calculated standardised odds ratios (ORs) for all analysed hormones to determine which hormones had the largest effect on autism likelihood (Fig. 3). Each hormone was standardised by its median and interquartile range, so that a one-unit increase in a hormone corresponded to the movement from the 25th to the 75th percentile of its range. Progesterone and oestradiol had the highest standardised ORs, with a movement from the 25th to 75th percentile of

these hormones incurring nearly a 50% increase in autism likelihood. Oestrone and oestrone sulphate also had ORs over 1. In contrast, increases in testosterone or androstenedione levels were not associated with increases in likelihood of diagnosis with statistical confidence.

The aromatising of testosterone (T) to oestradiol (E2) and of androstenedione (A) to oestrone (E1) were indirectly assessed by calculating their ratios, following

**Fig. 2** Heatmap and dendrogram of the pairwise correlations between the steroid hormones assayed in amniotic fluid. Asterisk denotes statistical significance ( $q < 0.05$ ), following correction via FDR. P progesterone, A androstenedione, T testosterone; P-OH 17-OH-progesterone, C cortisol, E-S oestrone sulphate, E2 oestradiol



**Fig. 3** Standardised odds ratios (ORs) for autism diagnosis for all amniotic steroids assayed to date. Each hormone was standardised by its median and interquartile range, so that a one-unit increase in a hormone corresponded to the movement from the 25th to the 75th percentile of its range

log-transformation and subtraction of their raw values. The two ratios were highly correlated with each other (Spearman's rho = 0.5855,  $p < 0.001$ ) but were not significantly different between autism cases and neurotypical controls (T/E2: Wilcoxon rank-sum  $w = 11186$ ,  $p = 0.1364$ ) (A/E1: Wilcoxon rank-sum  $w = 11032$ ,  $p = 0.2038$ ).

## Discussion

This study reports the first evidence that elevated levels of prenatal amniotic oestradiol, oestriol and oestrone are each associated with autism, with oestradiol levels being the most significant predictor of autism likelihood in univariate logistic regression models. These findings complement earlier observations that elevated steroidogenic activity is

associated with autism in the same samples derived from the Danish Historic Birth cohort [15]. We also calculated standardised ORs, in order to directly compare the effect sizes of all amniotic steroids measured to date. We found that oestradiol had the strongest positive effect size on autism likelihood, followed by oestrone, oestriol and progesterone (Fig. 3). This finding appears to contradict an earlier report by Windham et al. [32] that showed that lower levels of oestriol in second trimester were modestly associated with a later diagnosis of autism in the offspring. However, our samples correspond to a slightly earlier time point in pregnancy compared to Windham et al. (mean gestational week = 14.9 vs. 17.2 respectively) (see Table 1) [32], which could potentially better capture the steroid surge during the PMW [14]. Furthermore, our samples are of different origin, as Windham et al. assayed maternal serum, rather than foetal amniotic fluid. Steroid hormone levels in maternal serum do not differ relative to the baby's sex and do not correlate to amniotic levels during the PMW [42]. Therefore, amniotic oestrogens are arguably more relevant to the current research question than are maternal serum oestrogens.

A discrepancy in oestrogen levels between the mother and child could potentially be attributed to the placenta, which acts as an endocrine regulator of the maternal–foetal interface and the main source of oestrogen production for the foetus via the aromatisation of androgens [43]. Several lines of evidence suggest a contributory role for the placenta in the aetiology of autism. First, there is increased placental inflammation in autism [44]. Second, there is atypical placental morphology [45] and increased placental size [46] in cases of autism and at high familial risk respectively. Third, complications related to the placenta (pre-eclampsia [47],

hypertensive disorders [48]) are also more frequent in pregnancies that lead to autism. As with autism, placental dysfunction also disproportionately affects males more than females [49].

Given the high pairwise correlations between many of the steroid hormones (Fig. 2, Supplementary Table 3), as well as a lack of difference in aromatisation between cases and controls, our data suggest that an increase in foetal oestrogens is secondary to increased activity along the entirety of the steroidogenic axis in pregnancies that later result in autism [15]. Interestingly, oestradiol was not significantly correlated to testosterone (Pearson's  $\beta = 0.007$ ,  $p = 0.9103$ ) despite their proximity in steroidogenesis. This discrepancy may be because oestrogens are also de novo produced by the placenta, in addition to being aromatised from foetal and maternal androgens [43, 50]. Thus, a multi-systems approach is needed in order to clarify the causes of elevated foetal oestrogens in autism.

In the brain, oestrogen-mediated signalling on GABAergic neurons in the hypothalamus is required in order to suppress the steroidogenic axis [51]. Inefficient suppression of this axis in autism could be due to inefficient aromatisation of androgens in the hypothalamus, resistance to oestrogen signalling and/or dysfunction of the GABAergic system. Prenatally, foetal genetics (e.g. due to mutations in aromatase [52] or aromatase activators [53]), pregnancy complications (e.g. placental size [46]), as well as maternal risk factors (e.g. PCOS [18]) could all affect various points in this pathophysiologic pathway. These speculations would require further testing. Specifically for aromatisation, ratios based on circulating hormone levels may not be sufficient to capture tissue-specific activity, since aromatase is differentially regulated by separate promoters in the placenta, the adrenals and the brain [54].

High levels of prenatal oestrogens could dysregulate many aspects of prenatal endocrinology and affect prenatal brain development in areas that are not restricted to sexual differentiation. Several lines of evidence support a wider role of oestradiol as a 'neurosteroid' with many regulatory properties [55]. For example, disruption of oestrogen signalling in the developing cerebellum of mice reduces Purkinje cell growth in both males and females, but only reduces social behaviour in male mice, suggesting that the cerebellum may react to oestrogenic disruption in a sexually dimorphic way [56]. In early development, oestradiol decreases GABAergic signalling [57] and mediates its postnatal shift from excitation to inhibition [28, 58]. Oestrogens both increase the number of spines on embryonic primary cortical neurons [55] and induce the recruitment of proteins necessary for excitatory synapse formation, such as neuroligin-1, NMDA subunit GluN1, and post-synaptic density protein 95 (PSD-95) to the spines [59]. Higher levels of prenatal oestrogens might therefore increase the

number of excitatory synapses in the cortex, increasing the likelihood for autism, as suggested by the excitatory/inhibitory (E-I) theory of autism [60]. The perceptual phenotype in autism is characterised by reduced GABAergic inhibition, as shown using paradigms such as binocular rivalry [61] and attention to detail [62]. Oestrogen signalling could thus be a significant modulator of neuronal inhibition, particularly during early brain development and the 'critical period' of cortical plasticity, which is heavily reliant on the GABAergic system [63].

Although oestradiol (aromatised from testosterone) is the main prenatal masculinising agent in most mammals [24], its role in human sexual differentiation remains unclear. Men with aromatase deficiency have typical development of their urogenital tract [64], but may have cognitive disabilities, lack a growth spurt, and have atypical secondary sexual characteristics such as feminised body proportions in adulthood [65]. Oestrogens may therefore both feminise and masculinise humans, depending on the target tissue and developmental milieu. In autism, cognitive styles and sexually dimorphic neuroanatomy show some masculinised phenotypes [7, 9, 10], but functional connectivity and physical growth show a mixed pattern of masculine and feminine shifts [8, 66]. Prenatally though, and particularly during the masculinisation window, the process of sexual differentiation is understood to be directionally masculine over an anatomically and physiologically female default. The observed high levels of foetal oestrogens could thus be contributing to developmental cognitive differences [10], according to the "extreme male brain" theory of autism.

There was no statistically significant univariate, logistic association between autism and testosterone or androstenedione, which act via the androgen receptor. Mechanisms through which androgenic signalling could increase autism likelihood, which may have been missed in this analysis, include additional androgens or other agonists of the androgen receptor (e.g. neurosteroids like dehydroepiandrosterone [67]), interaction effects between androgens and oestrogens (e.g. coactivation of the androgen receptor by oestradiol [68]), as well as non-linear associations of androgens to autism likelihood. Consequently, androgenic activity may still be an important feature in the development of autism, as suggested by related clinical comorbidities [18, 69] and shown in associations of foetal testosterone to autistic traits in a separate cohort [70].

We could not test whether prenatal oestrogens were associated with autism likelihood in females as there were too few diagnosed women in the HBC in this time window. We plan to test this by expanding the time window. Thus, at present, our findings only generalise to males. Furthermore, comparison of the concentrations of androgens and cortisol to oestrogens is potentially confounded by the fact that the

latter were analysed at a later time point and underwent an additional freeze–thaw cycle. We have attempted to minimise any potential sources of confounding by using the same assay methodology with the initial analysis (LC-MS/MS), as well as reassessing for any differences in total storage time in this subset of the original cohort (Table 1).

Another limitation of this study is its reliance on clinical diagnoses from the Danish Central Psychiatric Register, which we could not be independently validated. However, a previous validation study of childhood autism diagnoses in the Danish Central Psychiatric Register found that 94% of diagnoses between 1990 and 1999 in the register were valid using a standardised coding scheme [71]. Similarly, we cannot be certain about the source of amniotic steroids, as they could be of foetal, maternal or placental origin. Foetal plasma and amniotic fluid are in osmotic equilibrium until the foetal skin is keratinised (typically by 25 weeks of gestation) [72]. Therefore, steroid concentrations in amniotic fluid accurately reflect those in foetal circulation.

In conclusion, we have demonstrated that prenatal oestradiol, oestriol and oestrone are elevated in boys who went on to develop autism. This extends our previous finding of elevated prenatal steroidogenesis in the same cohort and provides further evidence for the prenatal steroid theory of autism [15]. High levels of prenatal oestradiol contribute to a greater degree to autism likelihood than other prenatal sex steroids, including testosterone. We conclude that prenatal oestrogenic excess is a characteristic of autism and may interact with genetic predisposition to affect neurodevelopment.

**Acknowledgements** This study was supported by grants to SB-C by the Autism Research Trust, the Medical Research Council and the Wellcome Trust. This study was conducted using the Danish National Biobank resource supported by the Novo Nordisk Foundation. The research was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care East of England at Cambridgeshire and Peterborough NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. AP was funded by a doctoral scholarship from Trinity College Cambridge. AT was funded by a doctoral scholarship from Peterhouse Cambridge. This study also benefitted from support from the NIHR Cambridge Biomedical Research Centre and the Templeton World Charitable Foundation. We are grateful for discussions with Ken Ong, John Perry, David Dunger, Gordon Smith, Mike Lombardo and Varun Warrier.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Fombonne E. Epidemiology of pervasive developmental disorders. *Pediatr Res.* 2009;65:591–8.
2. Baron-Cohen S, Lombardo MV, Auyeung B, Ashwin E, Chakrabarti B, Knickmeyer R. Why are autism spectrum conditions more prevalent in males? *PLoS Biol.* 2011;9:e1001081.
3. Robinson EB, Lichtenstein P, Anckarsäter H, Happé F, Ronald A. Examining and interpreting the female protective effect against autistic behavior. *Proc Natl Acad Sci USA.* 2013;110:5258–62.
4. Jacquemont S, Coe BP, Hersch M, Duyzend MH, Krumm N, Bergmann S, et al. A higher mutational burden in females supports a “female protective model” in neurodevelopmental disorders. *Am J Hum Genet.* 2014;94:415–25.
5. Werling DM, Geschwind DH. Recurrence rates provide evidence for sex-differential, familial genetic liability for autism spectrum disorders in multiplex families and twins. *Mol Autism.* 2015;6:1–14.
6. Loomes R, Hull L, Mandy WPL. What is the male-to-female ratio in autism spectrum disorder? a systematic review and meta-analysis. *J Am Acad Child Adolesc Psychiatry.* 2017;56:466–74.
7. Lai MC, Lombardo MV, Suckling J, Riugrok AN, Chakrabarti B, Ecker C, et al. Biological sex affects the neurobiology of autism. *Brain.* 2013;136(Pt 9):2799–815.
8. Floris DL, Lai MC, Nath T, Milham MP, Di Martino A. Network-specific sex differentiation of intrinsic brain function in males with autism. *Mol Autism.* 2018;9:17.
9. Baron-Cohen S, Cassidy S, Auyeung B, Allison C, Achoukhi M, Robertson S, et al. Attenuation of typical sex differences in 800 adults with autism vs. 3,900 controls. *PLoS ONE.* 2014;9:e102251.
10. Greenberg DM, Warrier V, Allison C, Baron-Cohen S. Testing the empathizing-systemizing theory of sex differences and the extreme male brain theory of autism in half a million people. *Proc Natl Acad Sci USA.* 2018;115:12152–7.
11. Schwarz E, Guest PC, Rahmoune H, Wang L, Levin Y, Ingudomnukul E, et al. Sex-specific serum biomarker patterns in adults with Asperger's syndrome. *Mol Psychiatry.* 2011;16:1213–20.
12. Tan DW, Gilani SZ, Maybery MT, Mian A, Hunt A, Walters M, et al. Hypermasculinised facial morphology in boys and girls with Autism Spectrum Disorder and its association with symptomatology. *Sci Rep.* 2017;7:9348.
13. Hines M, Constantinescu M, Spencer D. Early androgen exposure and human gender development. *Biol Sex Differ.* 2015;6:3.
14. Welsh M, Suzuki H, Yamada G. The Masculinization Programming Window. *Endocr Dev.* 2014;27:17–27.
15. Baron-Cohen S, Auyeung B, Nørgaard-Pedersen B, Hougaard DM, Abdallah MW, Melgaard L, et al. Elevated fetal steroidogenic activity in autism. *Mol Psychiatry.* 2015;20:369–76.
16. Kosidou K, Dalman C, Widman L, Arver S, Lee BK, Magnusson C, et al. Maternal polycystic ovary syndrome and the risk of

- autism spectrum disorders in the offspring: a population-based nationwide study in Sweden. *Mol Psychiatry*. 2016;21:1441–8.
17. Berni TR, Morgan CL, Berni ER, Rees DA. Polycystic ovary syndrome is associated with adverse mental health and neurodevelopmental outcomes. *J Clin Endocrinol Metab*. 2018;103:2116–25.
  18. Cherskov A, Pohl A, Allison C, Zhang H, Payne RA, Baron-Cohen S. Polycystic ovary syndrome and autism: a test of the prenatal sex steroid theory. *Transl Psychiatry*. 2018;8:136.
  19. Manning JT, Baron-Cohen S, Wheelwright S, Sanders G. The 2nd to 4th digit ratio and autism. *Dev Med Child Neurol*. 2001;43:160–4.
  20. Ingudomnukul E, Baron-Cohen S, Wheelwright S, Knickmeyer R. Elevated rates of testosterone-related disorders in women with autism spectrum conditions. *Horm Behav*. 2007;51:597–604.
  21. Whitehouse AJ, Mattes E, Maybery MT, Dissanayake C, Sawyer M, Jones RM, et al. Perinatal testosterone exposure and autistic-like traits in the general population: a longitudinal pregnancy-cohort study. *J Neurodev Disord*. 2012;4:25.
  22. Kung KT, Constantinescu M, Browne WV, Noorderhaven RM, Hines M. No relationship between early postnatal testosterone concentrations and autistic traits in 18 to 30-month-old children. *Mol Autism*. 2016;7:15.
  23. Kung KT, Spencer D, Pasterski V, Neufeld S, Glover V, O'Connor TG, et al. No relationship between prenatal androgen exposure and autistic traits: convergent evidence from studies of children with congenital adrenal hyperplasia and of amniotic testosterone concentrations in typically developing children. *J Child Psychol Psychiatry*. 2016;57:1455–62.
  24. McCarthy MM. Estradiol and the developing brain. *Physiol Rev*. 2008;88:91–134.
  25. Konkle ATM, McCarthy MM. Developmental time course of estradiol, testosterone, and dihydrotestosterone levels in discrete regions of male and female rat brain. *Endocrinology* 2011;152:223–35.
  26. MacLusky NJ, Naftolin F. Sexual differentiation of the central nervous system. *Science*. 1981;211:1294–302.
  27. González M, Cabrera-Socorro A, Pérez-García CG, Fraser JD, López FJ, Alonso R, et al. Distribution patterns of estrogen receptor alpha and beta in the human cortex and hippocampus during development and adulthood. *J Comp Neurol*. 2007;503:790–802.
  28. Nunez JL, Aberdeen GW, Albrecht ED, McCarthy MM. Impact of estradiol on gamma-aminobutyric acid- and glutamate-mediated calcium responses of fetal baboon (*Papio anubis*) hippocampal and cortical neurons. *Endocrinology* 2008;149:6433–43.
  29. Durand CM, Perroy J, Loll F, Perrais D, Fagni L, Bourgeron T, et al. SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. *Mol Psychiatry*. 2012;17:71–84.
  30. Li J, Shi M, Ma Z, Zhao S, Euskirchen G, Ziskin J, et al. Integrated systems analysis reveals a molecular network underlying autism spectrum disorders. *Mol Syst Biol*. 2014;10:774.
  31. Puts NAJ, Wodka EL, Harris AD, Crocetti D, Tommerdahl M, Mostofsky SH, et al. Reduced GABA and altered somatosensory function in children with autism spectrum disorder. *Autism Res*. 2017;10:608–19.
  32. Windham GC, Lyall K, Anderson M, Kharrazi M. Autism spectrum disorder risk in relation to maternal mid-pregnancy serum hormone and protein markers from prenatal screening in California. *J Autism Dev Disord*. 2016;46:478–88.
  33. Tache V, Baer RJ, Currier RJ, Li CS, Towner D, Waetjen LE, et al. Population-based biomarker screening and the development of severe preeclampsia in California. *Am J Obstet Gynecol*. 2014;211:377.e1–377.e8.
  34. Talge NM, Holzman C, Senagore PK, Klebanoff M, Fisher R. Biological indicators of the in-utero environment and their association with birth weight for gestational age. *J Dev Orig Health Dis*. 2011;2:280–90.
  35. Walker CK, Krakowiak P, Baker A, Hansen RL, Ozonoff S, Hertz-Pannier I. Preeclampsia, placental insufficiency, and autism spectrum disorder or developmental delay. *JAMA Pediatr*. 2015;169:154.
  36. Moore GS, Kneitel AW, Walker CK, Gilbert WM, Xing G. Autism risk in small- and large-for-gestational-age infants. *Am J Obstet Gynecol*. 2012;206:314.e1–9.
  37. Lyall K, Pauls DL, Spiegelman D, Ascherio A, Santangelo SL. Pregnancy complications and obstetric suboptimality in association with autism spectrum disorders in children of the Nurses' Health Study II. *Autism Res*. 2012;5:21–30.
  38. Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G\*Power 3.1: tests for correlation and regression analyses. *Behav Res Methods*. 2009;41:1149–60.
  39. Weichman BM, Notides AC. Estrogen receptor activation and the dissociation kinetics of estradiol, estriol, and estrone. *Endocrinology* 1980;106:434–9.
  40. Korenman SG. Comparative binding affinity of estrogens. *Steroids* 1968;13:163–77.
  41. Sollberger S, Ehlert U. How to use and interpret hormone ratios. *Psychoneuroendocrinology*. 2016;63:385–97.
  42. van de Beek C, Thijssen JH, Cohen-Kettenis PT, van Goozen SH, Buitelaar JK. Relationships between sex hormones assessed in amniotic fluid, and maternal and umbilical cord serum: what is the best source of information to investigate the effects of fetal hormonal exposure? *Horm Behav*. 2004;46:663–9.
  43. Kaludjerovic J, Ward WE. The Interplay between Estrogen and Fetal Adrenal Cortex. *J Nutr Metab*. 2012;2012:837901.
  44. Straughen JK, Misra DP, Divine G, Shah R, Perez G, VanHorn S, et al. The association between placental histopathology and autism spectrum disorder. *Placenta*. 2017;57:183–8.
  45. Anderson GM, Jacobs-Stannard A, Chawarska K, Volkmar FR, Kliman HJ. Placental trophoblast inclusions in autism spectrum disorder. *Biol Psychiatry*. 2007;61:487–91.
  46. Park BY, Misra DP, Moye J, Miller RK, Croen L, Fallin MD, et al. Placental gross shape differences in a high autism risk cohort and the general population. *PLoS One*. 2018;13:e0191276.
  47. Dachew BA, Mamun A, Maravilla JC, Alati R. Pre-eclampsia and the risk of autism-spectrum disorder in offspring: meta-analysis. *Br J Psychiatry*. 2018;212:142–7.
  48. Curran EA, O'Keeffe GW, Looney AM, Moloney G, Hegarty SV, Murray DM, et al. Exposure to hypertensive disorders of pregnancy increases the risk of autism spectrum disorder in affected offspring. *Mol Neurobiol*. 2018;55:5557–64.
  49. Murji A, Proctor LK, Paterson AD, Chitayat D, Weksberg R, Kingdom J. Male sex bias in placental dysfunction. *Am J Med Genet A*. 2012;158A:779–83.
  50. Escobar JC, Patel SS, Beshay VE, Suzuki T, Carr BR. The human placenta expresses CYP17 and generates androgens de novo. *J Clin Endocrinol Metab*. 2011;96:1385–92.
  51. Pitteloud N, Dwyer AA, DeCruz S, Lee H, Boepple PA, Crowley WF Jr, et al. Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. *J Clin Endocrinol Metab*. 2008;93:784–91.
  52. Chakrabarti B, Dudbridge F, Kent L, Wheelwright S, Hill-Cawthorne G, Allison C, et al. Genes related to sex steroids, neural growth, and social-emotional behavior are associated with autistic traits, empathy, and Asperger syndrome. *Autism Res*. 2009;2:157–77.
  53. Sarachana T, Hu VW. Genome-wide identification of transcriptional targets of RORA reveals direct regulation of multiple genes associated with autism spectrum disorder. *Mol Autism*. 2013;4:14.

54. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Corbin CJ, Mendelson CR. Tissue-specific promoters regulate aromatase cytochrome P450 expression. *Clin Chem.* 1993;39:317–24.
55. Srivastava DP, Woolfrey KM, Liu F, Brandon NJ, Penzes P. Estrogen receptor beta activity modulates synaptic signaling and structure. *J Neurosci.* 2010;30:13454–60.
56. Hoffman JF, Wright CL, McCarthy MM. A critical period in purkinje cell development is mediated by local estradiol synthesis, disrupted by inflammation, and has enduring consequences only for males. *J Neurosci.* 2016;36:10039–49.
57. Mukherjee J, Cardarelli RA, Cantaut-Belarif Y, Deeb TZ, Srivastava DP, Tyagarajan SK, et al. Estradiol modulates the efficacy of synaptic inhibition by decreasing the dwell time of GABA<sub>A</sub> receptors at inhibitory synapses. *Proc Natl Acad Sci USA.* 2017;114:11763–8.
58. Ganguly K, Schindler AF, Wong ST, Poo M. GABA itself promotes the developmental switch of neuronal GABAergic responses from excitation to inhibition. *Cell.* 2001;105:521–32.
59. Sellers KJ, Erli F, Raval P, Watson IA, Chen D, Srivastava DP. Rapid modulation of synaptogenesis and spinogenesis by 17 $\beta$ -estradiol in primary cortical neurons. *Front Cell Neurosci.* 2015;9:137.
60. Rubenstein JLR, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. *Genes Brain Behav.* 2003;2:255–67.
61. Robertson CE, Kravitz DJ, Freyberg J, Baron-Cohen S, Baker CI. Slower rate of binocular rivalry in autism. *J Neurosci.* 2013;33:16983–91.
62. Robertson CE, Kravitz DJ, Freyberg J, Baron-Cohen S, Baker CI. Tunnel vision: sharper gradient of spatial attention in autism. *J Neurosci.* 2013;33:6776–81.
63. Hensch TK. Critical period plasticity in local cortical circuits. *Nat Rev Neurosci.* 2005;6:877–88.
64. Rochira V, Carani C. Aromatase deficiency in men: a clinical perspective. *Nat Rev Endocrinol.* 2009;5:559–68.
65. Chen Z, Wang O, Nie M, Elison K, Zhou D, Li M, et al. Aromatase deficiency in a Chinese adult man caused by novel compound heterozygous CYP19A1 mutations: effects of estrogen replacement therapy on the bone, lipid, liver and glucose metabolism. *Mol Cell Endocrinol.* 2015;399:32–42.
66. Bejerot S, Eriksson JM, Bonde S, Carlstrom K, Humble MB, Eriksson E. The extreme male brain revisited: gender coherence in adults with autism spectrum disorder. *Br J Psychiatry.* 2012;201:116–23.
67. Lu S-F, Mo Q, Hu S, Garippa C, Simon NG. Dehydroepiandrosterone upregulates neural androgen receptor level and transcriptional activity. *J Neurobiol.* 2003;57:163–71.
68. Yeh S, Miyamoto H, Shima H, Chang C. From estrogen to androgen receptor: A new pathway for sex hormones in prostate. *Proc Natl Acad Sci USA.* 1998;95:5527.
69. Pohl A, Cassidy S, Auyeung B, Baron-Cohen S. Uncovering steroidopathy in women with autism: a latent class analysis. *Mol Autism.* 2014;5:27.
70. Auyeung B, Taylor K, Hackett G, Baron-Cohen S. Foetal testosterone and autistic traits in 18 to 24-month-old children. *Mol Autism.* 2010;1:11.
71. Lauritsen MB, Jørgensen M, Madsen KM, Lemcke S, Toft S, Grove J, et al. Validity of childhood autism in the Danish Psychiatric Central Register: findings from a cohort sample born 1990–1999. *J Autism Dev Disord.* 2010;40:139–48.
72. Underwood MA, Gilbert WM, Sherman MP. Amniotic fluid: not just fetal urine anymore. *J Perinatol.* 2005;25:341–8.